Cymabay Therapeu (CBAY)

NASDAQ
3.940
0.000(0.00%)
  • Volume:
    72,059
  • Bid/Ask:
    3.930/3.940
  • Day's Range:
    3.940 - 3.980

CBAY Overview

Prev. Close
3.94
Day's Range
3.94-3.98
Revenue
-
Open
3.98
52 wk Range
3.8-9.06
EPS
-0.8
Volume
72,059
Market Cap
271.84M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
738,596
P/E Ratio
-
Beta
1.16
1-Year Change
10.99%
Shares Outstanding
68,995,772
Next Earnings Date
Aug 12, 2021
What is your sentiment on Cymabay Therapeu?
or
Vote to see community's results!

Cymabay Therapeu News

Cymabay Therapeu Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell

Cymabay Therapeu Company Profile

Cymabay Therapeu Company Profile

Employees
41

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Read More
  • Oppenheimer is manipulating this stock.
    0
    • Why?
      0
  • tomorrows direction?
    0
    • stagnant
      0
      • what gives?
        0
    • Test trials approved...going sky high today!
      2
      • It's moving today!
        0
        • not good forecast outlook for this stock.
          1
          • getting ready to cut my losses on this one...
            0
            • well for the month hoddle it's on the up
              0
          • Why has a strong buy? Dont get it
            0
            • Is tomorrow going up?
              1
              • sure😂😂😂
                0
              • going down
                0
              • Hopepully today is upper 💪🏻
                0
            • CMO bails, Orbimed sells all? This is dead.
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.